This episode brings together three leaders working at the intersection of pediatric innovation, health security, and early-stage commercialization. Kolaleh Eskandanian, Program Director of SPARK, is joined by founders Dori Jones of AcQumen Medical and Jugal Suthar of Vesynta for a conversation about advancing breakthrough solutions for children. They discuss the mission behind the BARDA-funded SPARK for Innovations in Pediatrics Hub at Children’s National Hospital, the challenges of developing technologies for pediatric populations, and the impact of public-private partnerships in moving lifesaving tools to market. Dori and Jugal share what their companies are building, the inflection points that shaped their journeys, and how BioHealth Innovation’s Entrepreneur-in-Residence program supported their progress. The group reflects on lessons learned, the value of mentorship, and how collaborative accelerator ecosystems help drive breakthroughs in pediatric care, preparedness, and health equity.
Listen now on your favorite podcast platform:
Apple: https://apple.co/48vNLoj
Spotify: https://bit.ly/4riG5wW
iHeart Podcasts: https://ihr.fm/4i35UNB
Amazon Podcasts: https://amzn.to/4ih5F1e
YouTube Podcasts: https://bit.ly/4ptuIAS
TuneIn: https://bit.ly/4ptw26O
Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).
Dr. Kolaleh Eskandanian is a nationally recognized leader in pediatric health innovation with more than twenty years of experience across academia, government, and industry. She previously served as Vice President and Chief Innovation Officer at Children’s National Hospital, where she founded Innovation Ventures and secured significant federal funding, patents, and licensed technologies. She now leads the BARDA-funded SPARK Accelerator Hub for Pediatrics and serves as Chief Strategy and Innovation Officer at Compremium AG, while also supporting early-stage innovators as an angel investor with Citrine Angels.
Dori Jones is the Co-Founder and CEO of AcQumen Medical, a medtech company developing UltraTrac, the first ultrasound-guided impedance technology designed for rapid assessment of hemodynamics in critically ill infants and children. She brings nearly two decades of experience across R&D, clinical education, and commercialization roles supporting cardiac and critical care devices at organizations ranging from early startups to Abbott and Medtronic. Her commitment to pediatric innovation is shaped in part by her experience as the mother of a NICU and PICU patient.
Dr. Jugal Suthar is the Co-Founder and CEO of Vesynta, a precision medicine company developing the DosoLogic platform, the first marketplace-enabled precision prescribing software aimed at improving accuracy and safety for every patient. His background includes clinical work as a hospital pharmacist and roles in drug development in the pharmaceutical industry. His PhD in precision medicine fuels his focus on bringing personalized dosing insights to populations often underrepresented in clinical research.
In this episode of BioTalk, CEO Gerard Eldering explains how Perfusion Medical is addressing a problem that trauma physicians and military medics have been struggling with for decades: capillary compression. Perfusion Medical is developing a drug aimed at treating hemorrhagic shock and other ischemic conditions. PM‑208 is a novel IV therapeutic designed to restore capillary blood flow, resolve ischemia, and protect vital organs. The team has advanced this work with $19 million in Department of Defense funding. He describes the scale of the unmet need, why PM‑208 is both organ- and disease‑agnostic, and how its simple formulation and strong safety profile position it for broad medical use.
In this episode of BioTalk, Rich Bendis sits down with Councilman Brian Knudsen, Jamie Schwartz of UNLV, and Vance Farrow from the Nevada Governor’s Office of Economic Development to spotlight the rapid emergence of Southern Nevada as a rising force in the biohealth landscape. The conversation covers the launch of the $10 million BioHealth Innovation Challenge, the Desert Forge Venture Fund, and the revitalization of BioTech Vegas, all designed to attract industry anchors, fuel early-stage startups, and cultivate a thriving innovation ecosystem. They also explore how strong collaboration between local and state government, academic institutions, and entrepreneurs is propelling Las Vegas into a new era of health innovation, with a focus on brain health, sports science, and workforce development.
Getting a biotech company off the ground takes more than science; it takes strategy, funding, and the right network. 
In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company’s cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen’s unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen’s broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland’s BioHealth Capital Region has supported the company’s innovation and growth.
